Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Meropenem × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 5 Other hematologic neoplasm 2 Lymphoid 1 Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

Docetaxel 344 pembrolizumab 272 Prednisone 241 Gemcitabine 230 enzalutamide 215 Radiotherapy 211 Nivolumab 209 Magnetic Resonance Spectroscopy 209 Cisplatin 171 Abiraterone Acetate 161 Radiosurgery 159 Leuprolide 154 Carboplatin 139 Sunitinib 137 bicalutamide 120 Specimen Handling 120 Goserelin 120 Androgen Antagonists 117 Ipilimumab 110 Paclitaxel 109 Cyclophosphamide 99 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 94 Everolimus 92 apalutamide 85 Bevacizumab 85 cabozantinib 82 abiraterone 79 Sorafenib 79 Radiation 79 atezolizumab 77

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05392634 2022-05-31

MACS

N.N. Petrov National Medical Research Center of Oncology

Phase 3 Unknown

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡